BIM Technology

The blood-brain barrier (BBB) penetrating technology is essential to develop drugs for neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, ALS, and Huntington’s disease, which have high unmet medical needs. MitoImmune has developed BIM Technology, a central nervous system target technology, and is conducting R&D for the treatment of neurodegenerative disease. BIM Technology is a structure-based multifunctional small-molecule technology that enhances the blood-brain barrier (BBB) permeability and the MIT Platform’s unique function which is mitochondrial-targeting ferroptosis inhibition.